A few key considerations can help guide the next steps
To be clear, GLP-1s are not FDA-approved for treating these conditions right now, but if more research proves they are safe and effective, they could receive formal approval for these uses (or others) in the future
Researchers are exploring how semaglutide, a medication for diabetes and weight loss, may affect chronic kidney disease
Small dose changes, added supports, or a switch to another medication often solve problems quickly when caught early
Disponible en: Barritt AS 4th, Marshman E, Noureddin M
Allosteric (off active site) activators were reported in the literature as early as the mid-2000s, but they had poor potency, poor pharmacokinetics, species-selective activity (human but not rodent), and none made it close to the clinic